Almac Doubles Global 2-8 °C Cold Room Capacity in Response to Increasing Biologics Demand
Almac has announced a significant investment to more than double the existing capacity of their 2–8 °C clinical supply labelling cold room facilities in the Group’s European and US-based facilities.
Additional dedicated temperature and humidity controlled labelling suites have been installed and are now live at Almac’s headquarter sites situated in Craigavon (UK), Souderton (PA) and Durham (NC) increasing their capacity to label temperature sensitive investigational products. This expansion represents the latest development in the company’s investment initiatives designed to meet growing client demand for specific services including a significant upsurge in clinical studies for biosimilar and biological investigational products.
The expansion of Almac’s cold room facilities adds significant capacity or clients requiring the development of valuable biologically sensitive investigational products, whilst complementing the company’s existing clinical supply chain management services.
Commenting on this latest expansion, Robert Dunlop, Managing Director of Almac’s Clinical Services Business Unit remarked: "We have witnessed significant growth in the biologics market in the past 12 months and this latest investment reflects both our on-going commitment to meeting the demands of the clinical trial market, as well as our ability to expand and adapt successfully to key developments within the pharmaceutical and biotech industries. These are exciting times for Almac as we continue to increase our range of services to deliver world class solutions to our global client base."
The cold room facilities expansion follows on from other recently announced investments including £54 million spent on the company’s pharmaceutical development and clinical services operations. This is in addition to the establishment of regional operations centres through strategic investments in Singapore and Japan geared towards meeting increasing customer demand in the Asia Pacific region.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.